Tag: Comprehensive Multiple Sclerosis Center

Poster-Disease-modifying Therapy

Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials

Background: CLASSIC-MS (NCT03961204) explores the long-term efficacy and durability of effect of cladribine tablets (CladT; cumulative dose...

Read More

Poster-Disease-modifying Therapy

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19

Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...

Read More